Dr. Aaron Tejani, PharmD gave this presentation on October 5th, 2019 in Vancouver, BC at the "Bringing Best Evidence to Clinicians" medical education conference marking the 25th anniversary of the UBC Therapeutics Initiative. Dr. Tejani is a clinical assistant professor with the Faculty of Pharmaceutical Sciences (University of British Columbia), Medication use evaluation pharmacist with Lower … [Read more...]
Sodium‐glucose Cotransporter 2 Inhibitors and the Risk for Urosepsis – A Multi‐site Prevalent New‐user Cohort Study
First published: 08 May 2020 Abstract AIMS The United States Food and Drug Administration has warned of an increased risk of serious urinary tract infection (UTI) and Fournier’s gangrene in patients with diabetes mellitus type 2 treated with sodium–glucose cotransporter 2 inhibitors (SGLT2i). However, evidence on these risks is limited. We aimed to compare urosepsis rates in SGLT2i users with … [Read more...]
Communicating emerging risks of SGLT2 inhibitors—timeliness and transparency of medicine regulators
BMJ 2020; 369:m1107 (Published 29 April 2020) DOI: https://doi.org/10.1136/bmj.m1107 Key messages Sodium glucose co-transporter-2 (SGLT2) inhibitors came to market amid heightened concern over the safety of diabetes drugs The drugs have received several serious safety warnings since approval, but the number, timeliness, and strength of these safety communications have differed … [Read more...]
[107] EMPA-REG OUTCOME Trial: What does it mean?
Empagliflozin (Jardiance) inhibits the sodium-glucose co-transporter 2 (SGLT2), which is the predominant mechanism responsible for reabsorption of glucose from the glomerular filtrate back into the circulation. By inhibiting SGLT2, empagliflozin increases urinary glucose excretion.1 Empagliflozin was approved by Health Canada in 2015 to improve glycemic control in adult patients with type 2 … [Read more...]
[103] Is the current ‘glucocentric’ approach to management of type 2 diabetes misguided?
A recent Alberta modeling study suggests that lifetime risk of diabetes is now 50% for non-indigenous Canadians and 80% for First Nations Canadians.1 If true, type 2 diabetes (DM2) will become the most common primary care diagnosis. Costs including medical visits, capillary blood glucose (CBG) testing, laboratory tests, and drug therapies will threaten other social priorities. In 2013, British … [Read more...]
Incretin based drugs and the risk of pancreatic cancer
In this large population study co-authored by Therapeutics Initiative researcher Dr. Colin Dormuth, "the use of incretin based drugs was not associated with an increased risk of pancreatic cancer compared with sulfonylureas. Although this potential adverse drug reaction will need to be monitored long term owing to the latency of the cancer, these findings provide some reassurance on the safety of … [Read more...]
